Free tool
Drug Trial Radar: Immunology and inflammation
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
90
Recruiting, industry sponsors, Immunology and inflammation, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,102
90 trials
Showing 1 to 25, recently updated first.
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184944 · 751 participants (planned) · Start Jan 22, 2026 · Primary completion Aug 13, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Colorado Springs, Colorado; Clermont, Florida; Kissimmee, Florida · 152 sites in all
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05835310 · 100 participants (planned) · Start Mar 14, 2024 · Primary completion Oct 5, 2028
Drug: Anifrolumab; Placebo · For: Systemic Lupus Erythematosus
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 111 sites in all
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184931 · 980 participants (planned) · Start Oct 1, 2025 · Primary completion May 14, 2029
Drug: Duvakitug; Placebo · For: Crohn's Disease
Sites: Peoria, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 481 sites in all
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07184996 · 980 participants (planned) · Start Oct 8, 2025 · Primary completion May 9, 2028
Drug: Duvakitug; Placebo · For: Ulcerative Colitis
Sites: Peoria, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 265 sites in all
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPivotal-lookingRecruiting
NCT06617325 · 450 participants (planned) · Start Nov 21, 2024 · Primary completion May 31, 2028
Drug: DZP · For: Systemic Lupus Erythematosus
Sites: Avondale, Arizona; Chandler, Arizona; Gilbert, Arizona · 247 sites in all
- A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06979453 · 366 participants (planned) · Start Dec 3, 2025 · Primary completion Oct 12, 2029
Drug: Deucravacitinib · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 137 sites in all
- A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)Pivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06405087 · 70 participants (planned) · Start Oct 27, 2025 · Primary completion Aug 12, 2030
Drug: Vedolizumab SC · For: Ulcerative Colitis; Crohn's Disease
Sites: Phoenix, Arizona; Loma Linda, California; Orange, California · 45 sites in all
- A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07250802 · 210 participants (planned) · Start Dec 4, 2025 · Primary completion Jul 3, 2034
Drug: Zasocitinib; Placebo and 1 more · For: Plaque Psoriasis
Sites: Chula Vista, California; Fountain Valley, California; Hialeah, Florida · 38 sites in all
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06430801 · 1,200 participants (planned) · Start Jun 5, 2024 · Primary completion Oct 30, 2028
Drug: IV Tulisokibart; SC Tulisokibart · For: Crohn's Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 499 sites in all
- A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07430306 · 245 participants (planned) · Start Apr 13, 2026 · Primary completion Jan 26, 2029
Drug: Anifrolumab · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 108 sites in all
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06819878 · 600 participants (planned) · Start Mar 17, 2025 · Primary completion Dec 31, 2028
Drug: Afimkibart; Placebo · For: Moderately to Severely Active Crohns Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 375 sites in all
- Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic DermatitisPivotal-lookingRecruiting
EHL Bio Co., Ltd.Industry
NCT07377838 · 286 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 2029
Drug: ADSTEM Inj.; Placebo · For: Atopic Dermatitis
Sites: Cheonan, South Korea
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07765888 · 375 participants (planned) · Start Aug 17, 2026 · Primary completion Mar 10, 2028
Drug: Tilrekimig; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 23 sites in all
- Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07286058 · 1,182 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 18, 2029
Drug: Zasocitinib · For: Psoriatic Arthritis
Sites: Tucson, Arizona; Fountain Valley, California; La Mesa, California · 111 sites in all
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06651281 · 1,380 participants (planned) · Start Nov 25, 2024 · Primary completion Dec 17, 2037
Drug: Tulisokibart; Placebo to tulisokibart · For: Crohn Disease; Colitis, Ulcerative
Sites: Bristol, Connecticut; Ypsilanti, Michigan; Liberty, Missouri · 37 sites in all
- Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07691970 · 1,072 participants (planned) · Start Aug 31, 2026 · Primary completion Dec 30, 2032
Drug: Anifrolumab · For: Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 166 sites in all
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07840287 · 404 participants (planned) · Start Oct 22, 2026 · Primary completion Sep 1, 2031
Drug: Enpatoran · For: Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
Sites: Troy, Michigan
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusPivotal-lookingRecruiting
Beeline Medicines CorporationIndustry
NCT07881120 · 390 participants (planned) · Start Nov 3, 2026 · Primary completion Apr 2030
Drug: Afimetoran; Placebo · For: Cutaneous Lupus Erythematosus (CLE); Systematic Lupus Erythematosus
Sites: San Diego, California; DeBary, Florida; Missoula, Montana
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DermatitisPivotal-lookingRecruiting
LEO PharmaIndustry
NCT06311682 · 195 participants (planned) · Start Jun 10, 2024 · Primary completion Oct 16, 2026
Drug: Tralokinumab + TCS; Placebo + TCS · For: Atopic Dermatitis
Sites: Birmingham, Alabama; North Little Rock, Arkansas; Palo Alto, California · 72 sites in all
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06133972 · 550 participants (planned) · Start May 21, 2024 · Primary completion Apr 3, 2034
Drug: Placebo; Ianalumab · For: Systemic Lupus Erythematosus
Sites: Anniston, Alabama; Burbank, California; La Palma, California · 167 sites in all
- Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06711887 · 348 participants (planned) · Start May 19, 2025 · Primary completion Aug 1, 2035
Drug: Ianalumab · For: Lupus Nephritis
Sites: Orchard Park, New York; Vitória, Brazil; Salvador, Brazil · 53 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07783425 · 1,375 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 8, 2028
Drug: Tilrekimig; Dupilumab · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Bryant, Arkansas · 50 sites in all
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisPivotal-lookingRecruiting
Arcutis Biotherapeutics, Inc.Industry
NCT07916480 · 415 participants (planned) · Start Oct 30, 2026 · Primary completion Apr 27, 2028
Drug: Roflumilast Cream 0.3%; Vehicle Cream · For: Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema)
Sites: Birmingham, Alabama; Bryant, Arkansas; Miami Lakes, Florida · 4 sites in all
- A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06807281 · 450 participants (planned) · Start Dec 2, 2025 · Primary completion Feb 22, 2032
Drug: Abrocitinib · For: Atopic Dermatitis
Sites: Birmingham, Alabama; North Little Rock, Arkansas; San Diego, California · 40 sites in all
- A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07298421 · 100 participants (planned) · Start Aug 18, 2026 · Primary completion May 31, 2030
Drug: Afimkibart · For: Moderately to Severely Active Crohns Disease
Sites: New York, New York; Harlingen, Texas; South Brisbane, Australia · 19 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.